DNA repair defects and implications for immunotherapy.
Explore this paper's citation graph
Summary
This observation has paved the way for further research investigating other sources of genomic instability that may serve as biomarkers to select patients for immunotherapy.
- Type
- review
- Published
- 2018-10-01
- Cited by
- 78
- References
- 91
- Access
- Open access
- OpenAlex
- https://openalex.org/W2893665301
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:52892606
Keywords
Genome instability, DNA repair, DNA damage, DNA mismatch repair, Carcinogenesis
References
- Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
- A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
- Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
- The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
- Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
- Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- MGMT gene silencing and benefit from temozolomide in glioblastoma.
- Re: Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk.
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Cited by
- New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
- Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
- Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy
- Pharmaceutical Management of Ovarian Cancer: Current Status
- Precision Cancer Trials With Immunomodulatory Agents
- Novel aspects of the preclinical pharmacology of platinum compounds
- Targeting DNA repair in cancer: current state and novel approaches
- Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
- The genomics of undifferentiated sarcoma of soft tissue: progress, challenges and opportunities.
- An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas.
- Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib
- An Elaborate STING Operation to Take Down NSCLC: Combination of Immunotherapies and Chemotherapies.
- Nine glycolysis-related gene signature predicting the survival of patients with endometrial adenocarcinoma
- Development and validation of an individualized DNA repair-related gene signature in localized clear cell renal cell carcinoma
- DNA damage checkpoint kinases in cancer
- De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection
- Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
- The importance of MLH1, MSH2, MSH6 and PMS2 in determining DNA damage response in digestive cancers
- DNA Mismatch Repair and its Role in Huntington’s Disease
- Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
Related papers
- Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers-possible diagnostic missteps trusting a single method.
- Microsatellite instability and mismatch repair defects in cancer.
- Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines
- Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review
- Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.
- Abstract IA008: Mismatch repair deficiency and survival in stage I endometrial cancer
- Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
- DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome
- Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus‐associated adenocarcinoma
- Local validation of microsatellite instability status in primary colorectal carcinomas